Article
Medical Laboratory Technology
Ming Li, Hong Lv, Siyuan Zhong, Shuling Zhou, Hongfen Lu, Wentao Yang
Summary: This study investigated the expression of FOXC1 protein in invasive breast cancer subtypes and found that FOXC1 expression is significantly higher in triple-negative breast cancer (TNBC). The study concluded that FOXC1 can be used as a specific marker for the triple-negative phenotype and as an additional diagnostic tool for the subclassification of TNBC.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
(2022)
Review
Oncology
Juan Zhang, Qi Tian, Mi Zhang, Hui Wang, Lei Wu, Jin Yang
Summary: Breast cancer is a common female cancer worldwide, with triple-negative breast cancer being one of the most dangerous subtypes with high mortality and relapse rates. Immunotherapy has become a promising and effective treatment, but not all patients are sensitive to it, highlighting the importance of selecting suitable candidates for immunotherapy. Recent discoveries in immune-related factors of TNBC offer insights into predicting prognosis and response to immunotherapy.
Article
Immunology
Angela Quintana, Enrique Javier Arenas, Cristina Bernado, Jose Fernandez Navarro, Jonatan Gonzalez, Anna Esteve-Codina, Teresa Moline, Merce Marti, Giuseppe Curigliano, Peter Schmid, Vicente Peg, Joaquin Arribas, Javier Cortes
Summary: The heterogeneity of immune infiltration in breast cancer is an important research area. This study found that the heterogeneity of TILs is related to the presence of immune infiltration, rather than patient characteristics.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Archana P. Thankamony, Sonny Ramkomuth, Shikha T. Ramesh, Reshma Murali, Priyanka Chakraborty, Nitheesh Karthikeyan, Binitha Anu Varghese, Vishnu Sunil Jaikumar, Mohit Kumar Jolly, Alexander Swarbrick, Radhika Nair
Summary: This study identifies a molecular mediator of intratumoral heterogeneity in breast cancer and validates its role in regulating the aggressive phenotype. The findings suggest that targeting this molecule with a transcriptional inhibitor could improve treatment of triple negative breast cancer.
FRONTIERS IN ONCOLOGY
(2023)
Article
Cell Biology
Yue Gong, Peng Ji, Yun-Song Yang, Shao Xie, Tian-Jian Yu, Yi Xiao, Ming-Liang Jin, Ding Ma, Lin-Wei Guo, Yu-Chen Pei, Wen-Jun Chai, Da-Qiang Li, Fan Bai, Francois Bertucci, Xin Hu, Yi-Zhou Jiang, Zhi-Ming Shao
Summary: This study investigated metabolic dysregulation in TNBCs using a multi-omics database, identifying three heterogeneous metabolic-pathway-based subtypes with distinct metabolic features. These subtypes had different prognoses, molecular subtype distributions, and genomic alterations, as well as varying sensitivities to metabolic inhibitors targeting fatty acid synthesis and glycolysis. Additionally, inhibition of lactate dehydrogenase could enhance tumor response to anti-PD-1 immunotherapy in specific TNBC subtypes.
Review
Oncology
Chengsen Chai, H. Helena Wu, Yasser Abuetabh, Consolato Sergi, Roger Leng
Summary: This review focuses on the role and regulation of PTEN in triple-negative breast cancer (TNBC). PTEN inactivation is associated with aggressive tumor phenotype and plays a crucial role in negatively regulating cell proliferation and migration. The review provides a summary of genomic alterations of PTEN, discusses the transcriptional regulation and posttranslational modifications of PTEN, and explores the prospects of PTEN protein in TNBC.
Review
Chemistry, Medicinal
Won-Ji Ryu, Joo Hyuk Sohn
Summary: Triple-negative breast cancer is a highly heterogeneous disease with limited therapeutic options as there are no appropriate targetable markers. Chemotherapy has been the mainstay treatment strategy, as tumors of this type do not respond to hormone therapy and HER2-targeted therapy.
Review
Oncology
Pere Llinas-Arias, Sandra Iniguez-Munoz, Kelly McCann, Leonie Voorwerk, Javier I. J. Orozco, Miquel Ensenyat-Mendez, Borja Sese, Maggie L. DiNome, Diego M. Marzese
Summary: The outcomes of triple-negative breast cancer (TNBC) are improving with the introduction of immunotherapy, but these responses are still limited to a select group of patients. Epigenetic alterations play a crucial role in immune escape mechanisms in TNBC, and the combination of epigenetic drugs and immunotherapy may enhance anticancer immune responses. Further research on the crosstalk between epigenetics and immune responses in TNBC is essential for developing effective therapeutic strategies.
Article
Oncology
Umar Mehraj, Umar Mushtaq, Manzoor A. Mir, Afnan Saleem, Muzafar A. Macha, Mohammad Nadeem Lone, Abid Hamid, Mohammed A. Zargar, Syed Mudasir Ahmad, Nissar Ahmad Wani
Summary: Tumor heterogeneity is a critical issue in the treatment of triple-negative breast cancer (TNBC), a highly diverse and aggressive subtype of cancer. Chemokines play a significant role in regulating TNBC heterogeneity. Understanding the chemokine networks involved in TNBC can lead to the development of effective therapeutic strategies.
SEMINARS IN CANCER BIOLOGY
(2022)
Article
Cell Biology
Chrysoula Tsirigoti, Mohamad Moustafa Ali, Varun Maturi, Carl-Henrik Heldin, Aristidis Moustakas
Summary: The transcription factor SNAI1 plays an important role in breast cancer by regulating cellular transformation, differentiation and migration. Loss of SNAI1 function may lead to changes in the phenotype of breast cancer cells and an increase in differentiation potential, possibly through the dual transcriptional action of FOXA1 and AR.
CELL DEATH & DISEASE
(2022)
Letter
Medicine, General & Internal
Ryan Sun, Lee-Jen Wei
Summary: This article discusses the clinical benefits of pembrolizumab combined with chemotherapy in patients with triple-negative breast cancer. The authors suggest that both hazard values and ratios should be considered when evaluating clinical benefits.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Biochemistry & Molecular Biology
Qi Xu, Jaspreet Kaur, Dennis Wylie, Karuna Mittal, Hongxiao Li, Rishab Kolachina, Mohammed Aleskandarany, Michael S. Toss, Andrew R. Green, Jianchen Yang, Thomas E. Yankeelov, Shristi Bhattarai, Emiel A. M. Janssen, Jun Kong, Emad A. Rakha, Jeanne Kowalski, Ritu Aneja
Summary: This study explores the intratumoral heterogeneity (ITH) in triple-negative breast cancer (TNBC) by evaluating gene expression and imaging differences within the same tumor. The results show extensive intertumoral heterogeneity and regional ITH in gene expression and image-derived features in TNBC. Concerns are raised regarding gene expression based TNBC subtyping.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Immunology
Seyedeh-Raheleh Niavarani, Guillaume St-Cyr, Lauren Daniel, Christine Lawson, Hugo Giguere, Almohanad A. Alkayyal, Lee-Hwa Tai
Summary: Triple negative breast cancer (TNBC) is a highly aggressive and difficult to treat subtype of breast cancer. Current treatment methods such as surgery, chemotherapy, and hormone/Her2 targeted therapies are not effective for TNBC patients. However, immunotherapies show promise in TNBC due to the high number of immune cells in the tumor. This preclinical study proposes a novel vaccination strategy using an oncolytic virus-infected cell vaccine to target TNBC.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Medicine, Research & Experimental
Kavya Anilkumar, L. P. Rema, Mithun Chacko John, T. Vanesa John, Alex George
Summary: Triple-Negative Breast Cancer (TNBC) is an aggressive and invasive type of breast cancer with limited treatment options. MiRNAs play a crucial role in TNBC progression and could serve as therapeutic or prognostic markers to unravel its complexity.
Article
Oncology
George Sflomos, Nora Schaumann, Matthias Christgen, Henriette Christgen, Stephan Bartels, Hans Kreipe, Laura Battista, Cathrin Brisken
Summary: Invasive lobular carcinoma (ILC) is a common subtype of breast cancer, often diagnosed at advanced stages. Up to 30% of ILC patients experience relapse, posing a treatment challenge. To address this, we have created a new in vivo model for ILC by grafting triple-negative human cancer cells into mice, which accurately recapitulates the different stages of ILC and provides a valuable tool for preclinical studies on TN ILC.
Article
Cell Biology
Jennifer L. Wilson, Simona Dalin, Sara Gosline, Michael Hemann, Ernest Fraenkel, Douglas A. Lauffenburger
INTEGRATIVE BIOLOGY
(2016)
Article
Biochemistry & Molecular Biology
Aharon Helman, Agnes Klochendler, Narmen Azazmeh, Yael Gabai, Elad Horwitz, Shira Anzi, Avital Swisa, Reba Condiotti, Roy Z. Granit, Yuval Nevo, Yaakov Fixler, Dorin Shreibman, Amit Zamir, Sharona Tornovsky-Babeay, Chunhua Dai, Benjamin Glaser, Alvin C. Powers-, A. M. James Shapiro, Mark A. Magnuson, Yuval Dor, Ittai Ben-Porath
Article
Multidisciplinary Sciences
Daphne Sun, Simona Dalin, Michael T. Hemann, Douglas A. Lauffenburger, Boyang Zhao
SCIENTIFIC REPORTS
(2016)
Article
Multidisciplinary Sciences
Leila Pirhaji, Pamela Milani, Simona Dalin, Brook T. Wassie, Denise E. Dunn, Robert J. Fenster, Julian Avila-Pacheco, Paul Greengard, Clary B. Clish, Myriam Heiman, Donald C. Lo, Ernest Fraenkel
NATURE COMMUNICATIONS
(2017)
Article
Oncology
Albert Grinshpun, Nancy Gavert, Roy Zvi Granit, Hadas Masuri, Ittai Ben-Porath, Shani Breuer, Aviad Zick, Shai Rosenberg, Myriam Maoz, Avital Granit, Eli Pikarsky, Ravid Straussman, Tamar Peretz, Amir Sonnenblick
CANCER BIOLOGY & THERAPY
(2018)
Article
Biochemistry & Molecular Biology
Albert Grinshpun, Naama Halpern, Roy Zvi Granit, Ayala Hubert, Tamar Hamburger, Yael Laitman, Einat Shacham-Shmueli, Yehudit Peerless, Eitan Friedman, Tamar Peretz
EUROPEAN JOURNAL OF HUMAN GENETICS
(2018)
Article
Multidisciplinary Sciences
Christopher W. Ng, Ferah Yildirim, Yoon Sing Yap, Simona Dalin, Bryan J. Matthews, Patricio J. Velez, Adam Labadorf, David E. Housman, Ernest Fraenkel
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2013)
Review
Medicine, Research & Experimental
Roy Z. Granit, Michal Slyper, Ittai Ben-Porath
WILEY INTERDISCIPLINARY REVIEWS-SYSTEMS BIOLOGY AND MEDICINE
(2014)
Article
Multidisciplinary Sciences
Nurcan Tuncbag, Pamela Milani, Jenny L. Pokorny, Hannah Johnson, Terence T. Sio, Simona Dalin, Dennis O. Iyekegbe, Forest M. White, Jann N. Sarkaria, Ernest Fraenkel
SCIENTIFIC REPORTS
(2016)
Article
Oncology
Simona Dalin, Mark R. Sullivan, Allison N. Lau, Beatrice Grauman-Boss, Helen S. Mueller, Emanuel Kreidl, Silvia Fenoglio, Alba Luengo, Jacqueline A. Lees, Matthew G. Vander Heiden, Douglas A. Lauffenburger, Michael T. Hemann
Article
Oncology
Noa Harpaz, Yair Eli Gatt, Roy Zvi Granit, Hila Fruchtman, Ayala Hubert, Albert Grinshpun
JOURNAL OF ONCOLOGY
(2020)
Article
Multidisciplinary Sciences
Helen S. Mueller, Colin E. Fowler, Simona Dalin, Enrico Moiso, Tee Udomlumleart, Salil Garg, Michael T. Hemann, Jacqueline A. Lees
Summary: Epigenetic regulators are crucial in cancer treatment, but resistance mechanisms to their inhibition are not well understood. A study on PRMT5 inhibitors in lung adenocarcinoma cell lines revealed a drug-induced transcriptional switch leading to rapid resistance. The resistant state, stabilized across LUAD variants, also showed vulnerabilities to other chemotherapeutics like paclitaxel, due to the presence of STMN2. This gene was found to be essential for both PRMT5 inhibition resistance and sensitivity to paclitaxel, highlighting a potential therapeutic combination for cancer treatment.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2021)
Article
Biochemistry & Molecular Biology
Ohad Tarcic, Roy Z. Granit, Ioannis S. Pateras, Hadas Masury, Bella Maly, Yaara Zwang, Yosef Yarden, Vassilis G. Gorgoulis, Eli Pikarsky, Ittai Ben-Porath, Moshe Oren
CELL DEATH AND DIFFERENTIATION
(2017)